Literature DB >> 15257859

Are angiotensin receptor blockers neuroprotective?

Christa Thöne-Reineke1, Mathias Zimmermann, Christian Neumann, Maxim Krikov, Jun Li, Nadja Gerova, Thomas Unger.   

Abstract

Stroke is one of the leading causes of invalidism and death in the industrialized world. Among others, the renin- angiotensin system (RAS) has been implicated in the pathogenesis and outcome of ischemic events, including stroke. Angiotensin II (Ang II), the major effector peptide of the RAS, exerts most of its well-defined physiologic and pathophysiologic actions, including those on the central and peripheral nervous system, through its Ang II type 1 (AT1) receptor subtype. This receptor not only contributes to stroke-related pathologic mechanisms (eg, hypertension, atherothrombosis, and cardiac hypertrophy) but also may be involved in postischemic damage to the brain. However, it has also been demonstrated that Ang II, via its AT2 receptor subtype, accelerates neuronal tissue regeneration after injury. In this article, we review the experimental evidence supporting the notion that blockade of brain AT1 receptors can be beneficial with respect to stroke incidence and outcome. We further delineate how AT2 receptors could be involved in neuronal regeneration following brain injury, such as stroke. In doing so, we also attempt to shed some light on the mechanisms by which AT1 receptor blockers, which leave the AT2 receptor unopposed, might exert protective actions in brain ischemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257859     DOI: 10.1007/s11906-004-0019-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  79 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.

Authors:  Y Inada; T Wada; M Ojima; T Sanada; Y Shibouta; R Kanagawa; Y Ishimura; Y Fujisawa; K Nishikawa
Journal:  Clin Exp Hypertens       Date:  1997-10       Impact factor: 1.749

3.  Angiotensin AT(2) receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells.

Authors:  U Stroth; A Blume; K Mielke; T Unger
Journal:  Brain Res Mol Brain Res       Date:  2000-05-31

4.  Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats.

Authors:  Peter Gohlke; Sebastian Von Kügelgen; Thomas Jürgensen; Thomas Kox; Wolfgang Rascher; Juraj Culman; Thomas Unger
Journal:  J Hypertens       Date:  2002-05       Impact factor: 4.844

Review 5.  Recent progress in angiotensin II type 2 receptor research in the cardiovascular system.

Authors:  M Horiuchi; M Akishita; V J Dzau
Journal:  Hypertension       Date:  1999-02       Impact factor: 10.190

Review 6.  Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases.

Authors:  H Matsubara
Journal:  Circ Res       Date:  1998 Dec 14-28       Impact factor: 17.367

7.  The angiotensin AT2 receptor modulates T-type calcium current in non-differentiated NG108-15 cells.

Authors:  B Buisson; S P Bottari; M de Gasparo; N Gallo-Payet; M D Payet
Journal:  FEBS Lett       Date:  1992-09-07       Impact factor: 4.124

8.  Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction.

Authors:  Y Nio; H Matsubara; S Murasawa; M Kanasaki; M Inada
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

9.  AT2 receptor stimulation induces generation of ceramides in PC12W cells.

Authors:  S Gallinat; S Busche; S Schütze; M Krönke; T Unger
Journal:  FEBS Lett       Date:  1999-01-22       Impact factor: 4.124

10.  Characterization of angiotensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells.

Authors:  M Tanaka; J Ohnishi; Y Ozawa; M Sugimoto; S Usuki; M Naruse; K Murakami; H Miyazaki
Journal:  Biochem Biophys Res Commun       Date:  1995-02-15       Impact factor: 3.575

View more
  11 in total

1.  Central depletion of angiotensinogen is associated with elevated AT1 receptors in the SFO and PVN.

Authors:  Sherry O Kasper; Carlos M Ferrario; Detlev Ganten; Debra I Diz
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 2.  Renin-angiotensin system blockers and modulation of radiation-induced brain injury.

Authors:  M E Robbins; W Zhao; M A Garcia-Espinosa; D I Diz
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

Review 3.  The protective arms of the renin-angiontensin system in stroke.

Authors:  Claudia A McCarthy; Lachlan J Facey; Robert E Widdop
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

4.  AT1 receptor antagonism does not influence early radiation-induced changes in microglial activation or neurogenesis in the normal rat brain.

Authors:  Kelly R Conner; M Elizabeth Forbes; Won Hee Lee; Yong Woo Lee; David R Riddle
Journal:  Radiat Res       Date:  2011-05-05       Impact factor: 2.841

Review 5.  Preventing vascular effects on brain injury and cognition late in life: knowns and unknowns.

Authors:  Owen Carmichael
Journal:  Neuropsychol Rev       Date:  2014-08-02       Impact factor: 7.444

6.  Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro.

Authors:  Tom N Grammatopoulos; Tiago F Outeiro; Bradley T Hyman; David G Standaert
Journal:  Biochem Biophys Res Commun       Date:  2007-09-21       Impact factor: 3.575

7.  Effects of the AT1 receptor antagonist L-158,809 on microglia and neurogenesis after fractionated whole-brain irradiation.

Authors:  Kelly R Conner; Valerie S Payne; M Elizabeth Forbes; Mike E Robbins; David R Riddle
Journal:  Radiat Res       Date:  2010-01       Impact factor: 2.841

8.  Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.

Authors:  Hans-Christoph Diener; Ralph L Sacco; Salim Yusuf; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  Lancet Neurol       Date:  2008-08-29       Impact factor: 44.182

9.  Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra.

Authors:  Tom N Grammatopoulos; Susan M Jones; Ferogh A Ahmadi; Brian R Hoover; Lawrence D Snell; Jesse Skoch; Vimal V Jhaveri; Andy M Poczobutt; James A Weyhenmeyer; W Michael Zawada
Journal:  Mol Neurodegener       Date:  2007-01-15       Impact factor: 14.195

10.  Blockade of Central Angiotensin II AT1 Receptor Protects the Brain from Ischemia/Reperfusion Injury in Normotensive Rats.

Authors:  Hamdolah Panahpour; Ali Akbar Nekooeian; Gholam Abbas Dehghani
Journal:  Iran J Med Sci       Date:  2014-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.